Aspirin has been a mainstay in the secondary prevention of cardiovascular events since the 1990s.¹ In the mid-1990s, the antiplatelet clopidogrel was tested against aspirin in patients with atherosclerotic vascular disease and was found to reduce vascular death, ischaemic stroke, and myocardial infarction by 8·7%.² The combination of clopidogrel and aspirin for secondary prevention to reduce cardiovascular events was tested in patients with symptomatic atherothrombosis; however, no benefit was observed.

中文翻译：

---

二级预防转变为二档

自1990年代以来，阿司匹林一直是心血管事件二级预防的中流tay柱。¹在1990年代中期，对动脉粥样硬化性血管疾病患者的抗血小板氯吡格雷进行了抗阿司匹林测试，发现其可将血管性死亡，缺血性中风和心肌梗塞降低8·7％。²对有症状的动脉粥样硬化血栓形成患者进行了氯吡格雷和阿司匹林联用的二级预防，以减少心血管事件。但是，没有观察到任何好处。